Citi's 2024 Global Healthcare Conference
Logotype for GoodRx Holdings Inc

GoodRx (GDRX) Citi's 2024 Global Healthcare Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for GoodRx Holdings Inc

Citi's 2024 Global Healthcare Conference summary

8 Jul, 2026

Retail environment and industry dynamics

  • Store closures, especially Rite Aid's, caused a $5 million headwind in the second half, with concentrated closures in Ohio and Michigan having the most impact.

  • Pharmacies have gained leverage in negotiations with PBMs due to unsustainable reimbursement rates, leading to a broader range of expected top-line growth (single-digit %) for next year.

  • Most renegotiations are expected to culminate by year-end, with new rates manifesting in January and February.

  • The current volatility is seen as a one-time reset, not a recurring theme, as pharmacy leverage is situational.

  • CVS store closures had minimal impact due to geographic thinning, while Rite Aid's concentrated closures created more friction for users.

Direct contracting and business strategy

  • Direct contracting with pharmacies increases their revenue and margin, with about 30% of volume now through such agreements and eight of the top 10 pharmacies signed up.

  • The hybrid strategy allows flexibility, letting retailers dictate preferences between direct contracts and PBM partnerships.

  • Direct contracts provide more control and merchandising opportunities, benefiting both parties and allowing for tailored pricing.

  • No PBM has stopped working with the company; relationships have evolved, with some PBMs now distributing GoodRx through integrated programs.

  • Direct contracting volume may accelerate or decelerate depending on PBM-pharmacy negotiations, but the approach remains adaptable.

Integrated Savings Program (ISP) and growth levers

  • ISP has grown to 5% of marketplace revenue and is expected to maintain healthy double-digit growth, with new deals signed for ISP wrap targeting off-formulary medications.

  • The most impactful growth lever is adding more plans and plan sponsors, with direct outreach to employers being a new focus.

  • Marketing costs for ISP are similar to D2C, with PBMs handling most go-to-market efforts.

  • Pushback from employers is mainly due to caution with new products, but comfort grows after successful implementation.

  • MedImpact, SilverScript, SmithRx, and Navitus are signed up for ISP wrap, with ongoing discussions to add more PBMs.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more